Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

PURPOSE: Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both. The goal of this randomized phase II study was to evaluate two differe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Clarke, Jennifer L., Iwamoto, Fabio M., Sul, Joohee, Panageas, Katherine, Lassman, Andrew B., DeAngelis, Lisa M., Hormigo, Adília, Nolan, Craig P., Gavrilovic, Igor, Karimi, Sasan, Abrey, Lauren E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2009
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727290/
https://ncbi.nlm.nih.gov/pubmed/19506159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.7944
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia